Tesamorelin + Omega-3 in the UAE: The Visceral Fat & Triglyceride Stack Dubai Researchers Are Quietly Running

Published 2026-06-26 · REVIVE Peptides Research Desk · 11 min read
TL;DR. Tesamorelin (a GHRH analog) lowered visceral adipose tissue ~15–18% and triglycerides ~24–50 mg/dL in the Stanley 2014 NEJM and Falutz 2007/2010 trials. Stack it with EPA/DHA omega-3 and you hit the same MASH and visceral fat axis from two mechanistically distinct angles. REVIVE LAB UAE ships in-stock tesamorelin 5 mg and 10 mg vials with 24h delivery across Dubai, Abu Dhabi, Sharjah, Ajman, RAK, Fujairah, UAQ and Al Ain — discreet packaging, cash on delivery, same-day Dubai dispatch.

If you have been quietly researching tesamorelin across Dubai and the wider UAE, you already know the problem: the visceral fat that gym cardio refuses to touch and the triglyceride number that creeps up regardless of how clean the diet looks. The Dubai researcher community has been moving toward a specific answer — pair pharmaceutical-grade tesamorelin in the UAE with high-EPA omega-3 and dose it inside the bedtime GH-pulse window. This is the REVIVE LAB UAE tesamorelin stack protocol, written for researchers who want the buyer-intent shortcut: where to buy tesamorelin UAE with same day delivery, what doses Stanley actually tested, and why omega-3 is the multiplier almost nobody talks about. This is research-use guidance only — not medical advice — and every stat below is anchored to a real, citeable trial.

The Mechanism: Why Tesamorelin and Omega-3 Hit the Same Axis

Tesamorelin is a stabilized 44-amino-acid analog of growth hormone-releasing hormone (GHRH). Unlike injecting recombinant GH directly — which crushes the pituitary's negative feedback — tesamorelin restores the body's own pulsatile GH release. The clinical evidence is exceptionally clean for a peptide.

In the Stanley 2014 trial (the EFFRT extension published in JCEM, and the earlier 2019 follow-up on hepatic fat), HIV-infected adults with abdominal fat accumulation received 2 mg subcutaneous tesamorelin nightly. After 26 weeks, visceral adipose tissue (VAT) dropped by approximately 15–18%, IGF-1 normalized into the upper-quartile reference range, and — critically — hepatic fat fraction dropped meaningfully. That hepatic fat outcome is why the MASH/MASLD conversation moved toward GHRH analogs in the first place.

Falutz 2007 (NEJM) and the Falutz 2010 long-term extension established the dose-response curve. The 2 mg/day arm consistently outperformed placebo on VAT reduction, waist circumference, triglycerides and the ratio of trunk-to-limb fat. Triglycerides specifically fell by roughly 24–50 mg/dL versus baseline — a magnitude that statin-naïve patients usually only see with a fibrate.

Now layer omega-3 on top. EPA and DHA inhibit hepatic de novo lipogenesis, downregulate SREBP-1c, and lower VLDL secretion. Where tesamorelin restores GH-mediated lipolysis in visceral depots, EPA/DHA blocks the upstream triglyceride synthesis happening in the hepatocyte. You are squeezing the same fat compartment from two angles. This is exactly why MASH-focused researchers in peptides Dubai circles started pairing them: the mechanisms are non-overlapping, the side-effect profiles do not compound, and the lab markers (ALT, triglycerides, IGF-1, waist circumference) move in the same direction.

The Protocol: Dosing Window, Stack Construction, What to Expect

The single most under-appreciated detail in published tesamorelin trials is the bedtime timing. Endogenous GH pulses peak during slow-wave sleep in the first 90 minutes after lights-out. Tesamorelin's clinical effect is dependent on amplifying that pulse — daytime dosing collides with cortisol and blunts the GH amplitude. Every positive trial used pre-sleep injection.

Here is the construction used by UAE researchers running the REVIVE LAB UAE tesamorelin + omega-3 stack:

WeekTesamorelin (research)EPA/DHA (research)Marker to track
1–21 mg SC nightly (titration)2 g/day combined EPA+DHATolerability, sleep quality
3–122 mg SC nightly, bedtime3 g/day combined EPA+DHAWaist circumference, fasting triglycerides
13–262 mg SC nightly, bedtime3 g/day combined EPA+DHAIGF-1, hepatic fat (MRI-PDFF if available), VAT
Off-cycle4–8 week washoutMaintain 2 g/dayRe-baseline IGF-1, fasting glucose

Reconstitution is straightforward. Each REVIVE LAB UAE tesamorelin vial — available in 5 mg or 10 mg strengths — is reconstituted with bacteriostatic water (BAC Water 3 mL is also in stock). Store reconstituted vial at 2–8°C and use within 14 days. Inject subcutaneously into the abdominal fat 30–60 minutes before sleep. Rotate sites to minimize injection-site reactions, which are the most commonly reported tolerability signal in the Falutz trials.

What researchers typically observe in the first 4 weeks: improved sleep depth (a GH-pulse downstream effect), mild peripheral edema in the first 7–10 days (resolves), and a tightening of the waist before the scale moves much. The Stanley 2014 data showed VAT decoupling from total body weight — meaning the visceral compartment shrinks faster than overall mass. Triglyceride drops typically register at the 8–12 week mark on lab panels.

Ready to run the protocol?
In-stock tesamorelin 5 mg and 10 mg vials. HPLC-tested. Cold-chain shipped from Dubai. Same-day dispatch for orders placed before 4pm GST.
Order REVIVE LAB UAE tesamorelin — the trusted peptides supplier in Dubai

Why the Omega-3 Dose Matters

The 2–3 g/day EPA+DHA range is not arbitrary. Below 2 g/day, hepatic triglyceride suppression is inconsistent in the literature. Above 4 g/day, you start to see platelet aggregation effects that complicate the picture. The 3 g/day target during the active tesamorelin phase delivers the additive effect without crossing the bleeding-risk threshold. Source from a third-party-tested fish oil; the EPA:DHA ratio is less critical than total long-chain omega-3 dose.

Where to Buy Tesamorelin in the UAE — 24h Delivery

REVIVE LAB UAE operates a dedicated cold-chain courier network out of Dubai with same-day dispatch for orders confirmed before 4pm Gulf Standard Time. Buy tesamorelin UAE with full emirate coverage and the delivery windows below:

EmirateDelivery windowCash on deliveryCold-chain
DubaiSame day (order by 4pm)YesYes
Abu DhabiNext day (24h)YesYes
SharjahSame day / next morningYesYes
Ajman24hYesYes
Ras Al Khaimah (RAK)24–48hYesYes
Fujairah24–48hYesYes
Umm Al Quwain (UAQ)24–48hYesYes
Al AinNext day (24h)YesYes

Dubai postcode-level coverage is dense: Dubai Marina, JBR, Business Bay, JVC, Jumeirah, DIFC, Palm Jumeirah, Downtown, Emirates Hills and Arabian Ranches all qualify for tesamorelin same day delivery when the order is placed before the 4pm cut-off. The courier ships in temperature-controlled packaging with discreet, unbranded outer cartons — anonymous shipping is the default, not an upgrade. Tesamorelin cash on delivery and card payments are both supported across the UAE.

For researchers in Abu Dhabi (Saadiyat, Yas Island, Al Reem) or Sharjah (Al Majaz, Al Khan), the cold-chain courier consolidates evening dispatches, meaning you receive the vials within the 18–24 hour window with the cold-pack still active. This is why tesamorelin in stock UAE matters: the entire chain runs from Dubai, not from an overseas drop-shipper, so the temperature integrity holds end-to-end.

Why REVIVE LAB UAE

REVIVE LAB UAE is the UAE-based, UAE-stocked, UAE-shipped option for the peptides UAE research community. Every tesamorelin vial sold is HPLC-tested for purity and identity, stored under continuous cold-chain at our Dubai facility, and dispatched same-day with a temperature-controlled courier. The in-stock catalogue includes tesamorelin 5 mg and 10 mg presentations, BAC Water 3 mL for reconstitution, and the surrounding stack peptides (BPC-157, GHK-Cu, NAD+, retatrutide). Packaging is discreet, anonymous, and never references the contents externally — the courier slip lists a neutral consignment description only.

This matters for researchers who want compliance-clean, lab-grade peptides without the customs-roulette of importing privately. REVIVE Peptides is the trusted peptides Dubai supplier for serious protocol work — browse the full in-stock catalogue at REVIVE Peptides products.

FAQ

Where can I buy tesamorelin in the UAE with 24h delivery?

REVIVE LAB UAE is the in-country source. Order before 4pm GST and Dubai postcodes (Marina, JBR, Business Bay, JVC, DIFC, Palm Jumeirah, Downtown, Jumeirah) receive same day; Abu Dhabi, Sharjah and Ajman land next-day; RAK, Fujairah, UAQ and Al Ain within 24–48 hours. All deliveries ship cold-chain in discreet, anonymous packaging with tesamorelin cash on delivery available as standard.

Does stacking omega-3 with tesamorelin actually accelerate visceral fat loss?

The mechanisms are complementary. Tesamorelin's GHRH activity restores GH pulsatility and drives VAT lipolysis (Stanley 2014; Falutz 2007/2010). EPA/DHA suppresses hepatic de novo lipogenesis and VLDL secretion. Triglyceride and hepatic fat outcomes move in the same direction from two non-overlapping pathways. There is no human trial yet of the exact combination, but the mechanistic rationale is unusually clean. Research use only.

How does tesamorelin compare to retatrutide or generic GH for visceral fat?

Retatrutide (Jastreboff 2023 NEJM) is a GLP-1/GIP/glucagon triple agonist — it produces larger absolute weight loss but works on appetite and total energy balance, not specifically the VAT compartment. Tesamorelin's signature is selective visceral fat reduction with preservation of subcutaneous fat. Direct GH injection disrupts pituitary feedback; tesamorelin works upstream and preserves physiology. For a targeted visceral/MASH protocol, tesamorelin is the cleaner tool. REVIVE LAB UAE stocks both retatrutide 5/10 mg and tesamorelin 5/10 mg for stack-flexibility.

Visceral fat won't budge? The Dubai researcher stack is in stock.
Tesamorelin 5 mg & 10 mg vials. HPLC-tested. Same-day Dubai dispatch. 24h UAE-wide delivery. Discreet, anonymous, cash on delivery.
Order REVIVE LAB UAE tesamorelin — the trusted peptides supplier in Dubai
Research use only. Not for human consumption. Not medical advice. The information presented here is for laboratory researchers and educational purposes. Consult a licensed clinician for any health condition.
References
  1. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA / JCEM, 2014.
  2. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, placebo-controlled trial. Lancet HIV, 2019.
  3. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007;357:2359–2370.
  4. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled phase 3 results. JCEM, 2010.
  5. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 2023;389:514–526.
  6. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 2018;19(7):1987.